FindTrial
Sign In

Efficacy of Ramelteon for preventing delirium in cancer patients: a systematic review

Efficacy of Ramelteon for preventing delirium in cancer patients: a systematic review - Efficacy of Ramelteon for preventing delirium in cancer patients: a systematic review

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000051786
Enrollment
Unknown
Registered
2023-08-01
Start date
2023-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients with cancer (more than or equal to 80%) 2.Patients without delirium before intervention 3.Studies examining the efficacy or safety of Ramelteon for the prevention of delirium in adult cancer patients The study design to be considered for inclusion is as follows: 1.If there were at least two randomized controlled trial (RCT)s, inclusion was completed. 2.If there were less than 2 RCTs, we included non-RCTs or observational studies with control groups. 3.If there were no RCTs/non-RCTs/observational studies with control groups, single-arm observational studies were considered for inclusion.

Exclusion criteria

Exclusion criteria: 1.Duplicate publications 2.Conference proceedings

Design outcomes

Primary

MeasureTime frame
Delirium incidence—

Secondary

MeasureTime frame
delirium severity, somnolence, tumbling and falls—

Countries

Japan

Contacts

Public ContactSaho Wada

National Cancer Center Division of Quality Assurance Programs

sawada@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026